← Human Trials & Peer-Reviewed Studies
Influence of endogenous cholinergic tone and growth hormone-releasing peptide-6 on exercise induced growth hormone release
Plain-language guide to PMID 9135702 (1997): randomized controlled trial study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRP-6.
Key Facts
- PMID
- 9135702
- Journal
- Clinical endocrinology
- Year
- 1997
- Study type
- Randomized Controlled Trial
- Authors
- Nooitgedagt A et al. (7 authors)
- DOI
- 10.1046/j.1365-2265.1997.1080919.x
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRP-6, published as a randomized controlled trial.
The neuroendocrine mechanisms of exercise-induced GH release remain incompletely understood.
In this study the researchers have investigated the influence of endogenous cholinergic tone and growth hormone-releasing peptide-6 (GHRP-6) on exercise induced GH release.
Who Took Part
By PubMed's age tags, the people studied were adults, men only.
How the Study Was Run
The design is described as randomized.
Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.
An indirect estimation of the secretory pattern of GH was calculated by the deconvolution technique.
The five tests were performed in random order after an overnight fast, and at least 3 days apart.
Serial blood samples from an indwelling catheter were taken before, during and after exercise for analysis of GH (IRMA), lactate (YSI 2300) and haematocrit (micromethod).
What Was Measured
The subject headings attached to it are Cholinesterase Inhibitors, Exercise, Growth Hormone, Growth Hormone-Releasing Hormone, Hematocrit, Lactic Acid and Oligopeptides.
What This Means in Plain Language
The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRP-6.
Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 1997 (Clinical endocrinology), a journal based in England.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the GHRP-6 compound page, all human trials.
Our Notes on the Compounds
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
GHRP-6: An early synthetic hexapeptide ghrelin-receptor agonist that releases growth hormone and strongly increases appetite.
Related Pages
- Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library
- GHRP-6 in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.